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Abstract
Introduction Atypical teratoid rhabdoid tumor (ATRT) is a
rare, highly malignant, and aggressive tumor of infancy. Al-
though the prognosis of ATRT has been extremely poor,
recently, the first prospective study for ATRT demonstrated
improvement of prognosis. On the other hands, oculomotor
nerve palsy is rare in children and the most frequent etiology is
congenital. To our knowledge, only a few ATRT cases pre-
senting with oculomotor nerve palsy have been reported, but
ATRT originating from the cavernous sinus (CS) has not yet
been reported.
Case report An 18-month-old girl with right oculomotor
nerve palsy was admitted, and a small mass in the right CS
was detected with brain MRI. Although she received steroid
pulse therapy and antimicrobial therapy, the mass continued to
enlarge. One month after admission, the mass was partially
resected and diagnosed as ATRT. Multimodal therapy includ-
ing anthracycline-based chemotherapy, intrathecal therapy,
and cranial irradiation was performed. Twenty-nine months
after resection, she was alive without tumor relapse, but the
oculomotor nerve palsy persisted.
Conclusion This is the first reported case of ATRT located in
the CS presenting with oculomotor nerve palsy. This case was
successfully treated with partial removal of the tumor, a new
chemotherapy regimen for ATRT and cranial X-ray
irradiation.
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Introduction
Atypical teratoid rhabdoid tumor (ATRT) is a rare, highly
malignant, and aggressive tumor of infancy. ATRT was clas-
sified as an embryonal grade IV neoplasm by the WHO in
1993 [1]. Although ATRT can originate from anywhere in the
central nervous system (CNS), tumor location is distributed
equally in the infratentorial and supratentorial regions, and
other regions are infrequent [2, 3]. Symptoms depend on
tumor location. To date, there has been no established standard
treatment for ATRT, and the prognosis has been extremely
poor [2–6]. However, recently, the first prospective study for
ATRT demonstrated improvement of prognosis [7].
Oculomotor nerve palsy is rare in children and the most
frequent etiology is congenital [8, 9]. To our knowledge, only
a few ATRT cases presenting with oculomotor nerve palsy
have been reported [10, 11], but ATRT originating from the
cavernous sinus (CS) has not yet been reported. Described is a
case of ATRT in the CS that presented with oculomotor nerve
palsy and was successfully treated with multimodal therapy.
Case
An 18-month-old girl presented with right ptosis of 7-day
duration. She was born prematurely at 31 weeks and 5 days
of gestational age, because of premature rupture of mem-
branes, and was delivered by cesarean section due to breech
presentation. Her body weight at birth was 1,624 g. There was
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no evidence of asphyxia or traumatic episodes around deliv-
ery. Her growth and development were not problematic. At the
age of 18 months, her parents noticed sudden onset right
ptosis. She suffered neither infectious disease nor cranial
trauma preceding the appearance of ptosis. Although her
general condition had not changed, she was admitted to our
hospital because her ptosis had progressed over 7 days. On
admission, she was afebrile and her vital signs were normal.
Physical and neurological examination did not reveal abnor-
mal signs, except for right ptosis. Eye examination was per-
formed by an ophthalmologist. The right eyelid was droopy,
and the right pupil was dilated and non-reactive to light. There
was exotropia and hypotropia of the right eye position. The
symptoms did not resolve with Tensilon. Although the results
of blood, urine, and cerebrospinal fluid (CSF) examinations
were unremarkable, brain magnetic resonance imaging (MRI)
revealed a 9×4 mm tumor at the right CS (Fig. 1a, b). There
was no evidence of a vascular lesion there with magnetic
resonance angiography (MRA). The etiology of her right
oculomotor nerve palsy was considered to be a CS tumor.
However, neurosurgical intervention (i.e., a biopsy or a resec-
tion of the tumor) was considered too difficult. The differential
diagnoses included inflammatory disease (including Tolosa-
Hunt syndrome) and lymphoma, and therefore, systemic cor-
ticosteroid pulse therapy was initiated on admission day 7, but
the nerve palsy did not improve with appropriate medical
treatment. Next, antimicrobial therapy was selected with sus-
picion of bacterial or fungal infection. Administration of
meropenem, voriconazole, and liposomal amphotericin B
showed no efficacy, and serological and culture examinations
demonstrated no evidence of infectious disease. Three weeks
after admission, she developed vomiting, and brain MRI
revealed that the CS tumor was rapidly enlarging. It had
grown to 30×20 mm with invasion into the pontine cistern
with compression of a part of the pons (Fig. 1c, d). On
admission day 31, the neurosurgery team performed a right
frontotemporal craniotomy and partial tumor resection. Ac-
cording to postoperative MRI, the extent of tumor resection
was about 50% (Fig. 1e, f). Pathologically, the tumor
consisted of diffuse proliferation of small undifferentiated
cells which resembled those of medulloblastoma (Fig. 2).
Immunohistochemically, a small number of the cells were
positive for SMA, EMA, and CD99. They were negative for
CAM5.2, AE1/AE3, synaptophysin, GFAP, neurofilament,
CD20, CD3, CD45RO, CD79a, and TdT. Lack of nuclear
reactivity for INI-1 was recognized. Thus, the tumor was
diagnosed as ATRT. Although chest and abdominal enhanced
computed tomography did not detect another lesion, CSF
examination 10 days after surgery revealed tumor cell prolif-
eration. She was diagnosed with right CS ATRT with CSF
dissemination.
Seven weeks after admission, chemoradiotherapy was ini-
tiated according to the Intergroup Rhabdomyosarcoma Study
III protocol [7]. At that time the tumor size returned to the
same size as before resection. This protocol consisted of
anthracycline-based chemotherapy, intrathecal therapy, and
Fig. 1 Brain MRI with gadolinium enhancement (axial and coronal
sections). On admission day 1, MRI revealed a 9×4 mm tumor at the
right cavernous sinus (a, b). Three weeks after admission, the cavernous
sinus tumor had rapidly increased to 30×20 mm in size. The tumor
invaded the cavernous sinus to the pontine cistern and compressed a part
of the pons (c, d). About 50% of the tumor was resected by surgery (e, f).
Six weeks after starting chemotherapy, the tumor size had reduced, and
only a 7×4 mm tumor remained at the pontine cistern (g, h)
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cranial irradiation. Brain MRI, 6 weeks after starting chemo-
therapy, showed that the tumor size was dramatically reduced,
and a 7×4 mm lesion remained at the pontine cistern
(Fig. 1g, h). Six weeks after starting chemotherapy, malignant
cells in the CSF were undetectable. Along with chemotherapy,
she received X-ray irradiation against the primary tumor bed
with a total dose of 54 Gy in 1.8 Gy fractions using intensity-
modified delivery. During 13 months of chemoradiotherapy,
serious and uncontrollable toxicity did not occur. At present,
29 months after initial resection, brain MRI revealed only a
5×5 mm residual lesion without enhancement at the pontine
cistern, which has not changed in size since completion of
chemoradiotherapy. However, she continues to have right
oculomotor nerve palsy and disturbance of speech
development.
Discussion
In children, oculomotor nerve palsy is uncommon. Excepting
congenital cases, the causes of oculomotor nerve palsy are
trauma, neoplasm, vascular abnormalities, and inflammation
in the region anywhere the nerve passes (such as the midbrain,
cavernous sinus, orbital fissure, orbit, and subarachnoid
space) [8, 9]. In the present case, the tumor within the CS
was considered to have caused the oculomotor nerve palsy.
The described etiologies for CS tumors have included infec-
tious disease, Tolosa-Hunt syndrome (THS), aneurysm,
thrombosis, and neoplasms [12]. Although neoplasms origi-
nating from the CS are rare in children, several case reports
concerning malignant lymphoma in the CS have been pub-
lished [13, 14]. In the present case, MRA ruled out vascular
lesions. Although tumor biopsy is necessary for diagnosis, in
general, neurosurgical biopsies of CS tumors are employed as
a last resort. So, corticosteroids were first administered for
diagnostic treatment of THS. It should be noted that steroid
therapy can be effective for neoplasms such as lymphoma
[14]. The present case did not respond to steroid therapy, so
THS was excluded. Both bacterial and fungal infections are
part of the differential diagnosis of CS tumors, but the present
case had no evidence of infection. Finally, partial resection of
the tumor and a pathological examination was performed, and
ATRTwas diagnosed.
ATRT is a rare but extremely aggressive malignant tumor
of infancy. ATRTcan occur at any site within the CNS, and the
symptoms are associated with the location of the tumor. Al-
though cranial nerve palsy has been described as a symptom
of ATRT, the majority of cases of abducens or facial nerve
palsy are due to infratentorial tumors [2]. To our knowledge,
only two case reports of ATRT with oculomotor nerve palsy
have been published. One case was a 6-week-old boy with
ATRT located in the interpeduncular cistern [10], and the other
was a 56-year-old woman with ATRT located in the sella [11].
The present patient had a novel ATRT with regards to the
location in the CS. Although neoplasms in the CS are rare in
children, and neurosurgical biopsy of a CS tumor is techni-
cally difficult, rapidly increasing tumors should be suspected
to be aggressive malignant tumors such as ATRT, and there-
fore, prompt biopsy is necessary.
As previously reported, the prognosis of ATRT has been
extremely poor [2–6]. Tekautz et al. reported that the 2-year
event-free and overall survival rates of children younger than
3 years of age were 11 and 17%, worse than in older patients
[15]. In a previous study, ATRT patients received chemother-
apy designed for other pediatric malignant brain tumors (such
as medulloblastomas and primitive neuroectodermal tumors),
and many ATRT patients younger than 3 years have had
cranial X-ray irradiation refused or delayed in order to avoid
long-term neurocognitive complications [4–6, 15]. The role of
high-dose chemotherapy with hematopoietic stem cell rescue
for ATRT is still controversial [16]. However, the first pro-
spective clinical trial for newly diagnosed ATRT in children
published in 2009 [7] demonstrated significant improvement
of prognosis, with a 2-year progression-free survival rate of
53% and an overall survival rate of 70%. In that trial, the
treatment regimen after resection consisted of anthracycline-
based chemotherapy, intrathecal therapy, and cranial X-ray
irradiation regardless of age. This chemoradiotherapy regimen
was adopted in the present report, and the patient has survived
without relapse for 29 months after tumor resection.
A recent retrospective study indicated that radiotherapy
improves survival outcome for ATRT [17], but there is no
published review for long-term complications of ATRT survi-
vors. In compensation for prolonged survival, the present
patient may experience long-term complications, including
Fig. 2 Pathological examination of the resected specimen. Hematoxylin
and eosin staining reveal diffuse proliferation of small undifferentiated
cells
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neurocognitive impairment due to cranial X-ray irradiation.
Bernstein et al. reported the first cohort of ATRT patients
treated with proton beam radiotherapy in 2013 [18]. They
described that 9 of 10 patients were alive without evidence
of disease with a median follow-up of 27.3 months. Proton
beam therapy is expected to reduce damage to normal tissue.
Although the assessment of long-term complications, espe-
cially neurocognitive outcomes, after proton beam radiation
compared with X-ray irradiation may require long-term
follow-up, the results of their study encourage to the adapta-
tion of proton therapy as a treatment strategy for ATRT
patients, particularly for younger patients. It is expected that
the original strategy for ATRT patients, such as high-dose
chemotherapy with hematopoietic stem cell rescue, proton
beam radiotherapy, and molecular targeting therapy, which is
equal in efficacy and has decreased long-term sequelae com-
pared with cranial X-ray irradiation, will be established in the
future.
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